Please Wait.....
Report
Neurology Market: A BCC Research Overview
Market Research Report I 2025-02-17 I 185 Pages I BCC Research
Description
Report Scope
This report includes a market analysis of the therapeutics used to treat neurological conditions. The study outlines the market potential for neurology medications for both now and in the future. It also provides a thorough examination of the market's drivers, constraints, and pipeline medications, as well as the competitive landscape, laws, epidemiology of neurological disorders, mergers and acquisitions. Market forecasts through 2029 are also covered in the report.
The report breaks down neurology market shares according to various disease indications. Parkinson's disease, Alzheimer's disease, psychotic disorder, epileptic disorder, autism disorder, multiple sclerosis, brain tumor, and other diseases are the neurological disorders that make up the market segmentation. Therapeutics and regional analysis are covered in each disease segment.
Anti-Parkinson's medications are covered in the Parkinson's disease market. The market is divided into different drug classes such as dopaminergic, enzyme inhibitors, dopamine agonists and other anti-Parkinson's drugs based on drug class. Anti-Alzheimer medications are part of the Alzheimer's disease market, which is divided into segments according to respective mechanisms of action. The market is divided into two segments based on drug class: NMDA antagonists and AChE inhibitors. Antipsychotic medications are part of the market for psychotic diseases. The market is divided into different drug classes, including D2 partial agonists, D2/5HT2A antagonists, and D2 antagonists.
Anti-epileptic medications are included in the market for epileptic diseases. The market is divided into three segments based on drug class: first-generation, second-generation and third-generation. Autism spectrum disorder drugs are included in the market. Based on information on labels, the market is divided into drug categories: off-label pharmaceuticals and pharmaceuticals with an ASD label. Brain tumor treatments are included in the market for brain tumors. The market is divided into different types of therapy, such as targeted therapy and chemotherapy.
In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. By geographical region, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Includes
- 52 data tables and 59 additional tables
- Analyses of the global market trends for neurology therapeutics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects, along with a market share analysis by type of disorder, drug classification, mechanism of action, label information, end user and region
- Facts and figures pertaining to key market dynamics, technology advances, pipeline drugs, regulations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage
- Discussion of therapeutics used for treatment of neurological disorders, along with coverage of novel pipeline drugs, patent expiries of blockbuster drugs and new drug approvals
- A patent analysis, including key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Novartis AG, UCB S.A, and Otsuka Holdings Co. Ltd.
Executive Summary
Summary:
The global market for neurology was valued at $63.0 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 7.1% to reach approximately $94.8 billion by the end of 2029. The neurology sector is dynamic and offers providers a wealth of opportunities for expansion.
The demand for medications to treat neurological diseases like Parkinson's, multiple sclerosis (MS) and Alzheimer's is expected to rise as their prevalence increases. Due to the availability of better healthcare infrastructure and the rise in the prevalence of chronic diseases, the market for neurological drugs is anticipated to grow at a rapid pace in unexplored emerging markets, including Asia-pacific countries. Additionally, the growing demand for better healthcare services and large government investments in healthcare infrastructure are driving the rapid development of the healthcare sector in emerging economies.
In 2023, the multiple sclerosis market segment held the largest share among disease indication segments. The market has grown significantly in recent years due to improvements in the creation of more potent treatment alternatives. Pharmaceutical companies are spending large sums of money on R&D in an effort to develop a new treatment that will either improve disease management or slow its progression. New technologies like telemedicine and personalized medicine are also making it simpler for patients to get timely, individualized care. The need for treatment solutions has increased as a result of growing patient numbers and increased awareness of MS. The psychotic segment held the second-highest share and generated $14.3 billion in revenue in 2023. Throughout the forecast period, it is expected to grow at a compound annual growth rate (CAGR) of 9.5%.
The segment pertaining to brain tumor diseases is anticipated to expand at the fastest rate (12.6%). The rising incidence of brain cancer worldwide, improvements in drug delivery to the brain via cell-mediated drug transport and nanotechnology, high healthcare costs, diagnostic technology advances, clinical trials and the creation of predictive markers for drug response are all factors contributing to the growth.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Porter's Five Forces Analysis
Potential for New Entrants (Low to Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate)
Threat of Substitute Products or Services (Moderate to High)
Industry Rivalry (High)
Medical Coding and Billing Challenges in Neurology
Step Therapy
Medicare Cuts
Coding errors
Use of Modifiers
Documentation
Coverage and Prior Authorization
Compliance and Audits
Reimbursement Rate and Denials
Physician Payment Challenges
Evaluation and Management (E/M) - Bill the Correct Level of Care
Negotiating Contracts
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Growing Geriatric Population with Neurological Disorders
Increasing Global Incidence of Neurological Disorders
Government and NGO Initiatives in Creating Awareness
Research Initiatives in Neurology
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
Adverse Side Effects
High Cost of Drug Development
Chapter 4 Emerging Trends and Pipeline Analysis
Emerging Trends
Precision Medicine in Neurological Disorders
Gene Therapy for Neurological Disorders
Neurodegeneration and Stem Cell Therapy
Nanotechnology in Neuroscience
Virtual Reality and Digital Therapeutics
Conclusion
Pipeline Analysis
Chapter 5 Regulatory Landscape
Overview
Cross-Disciplinary Value Story
High-Quality Patient-Reported Outcome Data
Impact of New EU and the U.S. Legislation
Conclusion
Chapter 6 Market Segmentation Analysis
Segmental Breakdown
Market Analysis by Disease Indication
Parkinson's Disease
Alzheimer's Disease
Psychotic Disorders
Epileptic Disorder
Autism Spectrum Disorder
Brain Tumor
Multiple Sclerosis
Others
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Company Share Analysis of Anti-Parkinson's Drugs
Company Share Analysis of Alzheimer's Disease Drugs
Company Share Analysis of Antipsychotic Drugs
Company Share Analysis of Anti-Epileptic Drugs
Company Share Analysis of ASD Therapeutics
Company Share Analysis of Brain Tumor Therapeutics
Company Share Analysis of Multiple Sclerosis Therapeutics
Chapter 8 Appendix
Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ALPHA COGNITION
BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
H. LUNDBECK A/S
LILLY
MERCK & CO. INC.
NOVARTIS AG
OTSUKA HOLDINGS CO. LTD.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB S.A.
List of Tables
Summary Table : Global Neurology Market, by Disease Indication, Through 2029
Table 1 : Navigate New Neurology-related Codes
Table 2 : Adverse Side Effects of Some Neurological Drugs
Table 3 : List of Some Clinical Trial Drugs for Parkinson's Disease in Phase 3 and 4
Table 4 : List of Some Clinical Trial Drugs for Alzheimer's Disease in Phase 3 and 4
Table 5 : List of Some Clinical Trial Drugs for Epilepsy Disorder in Phase 3 and 4
Table 6 : List of Some Clinical Trial Drugs for Autism Spectrum Disorders in Phase 3 and 4
Table 7 : List of Some Clinical Trial Drugs for Brain Tumors in Phase 3 and 4
Table 8 : List of Some Clinical Trial Drugs for Multiple Sclerosis in Phase 3 and 4
Table 9 : Global Neurology Market, by Disease Indication, Through 2029
Table 10 : Global Neurology Market for Anti-Parkinson's Drugs, by Drug Class, Through 2029
Table 11 : Global Neurology Market for Anti-Parkinson's Drugs, by Region, Through 2029
Table 12 : Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2029
Table 13 : Global Neurology Market for Alzheimer Drugs, by Region, Through 2029
Table 14 : Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2029
Table 15 : Some Novel Antipsychotic Drug Targets and Therapeutic Characteristics
Table 16 : Global Neurology Market for Antipsychotic Drugs, by Region, Through 2029
Table 17 : Global Neurology Market for Anti-Epileptic Drugs, by Drug Class, Through 2029
Table 18 : Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2029
Table 19 : Global Neurology Market for ASD Therapeutics, by Label Information, Through 2029
Table 20 : Global Neurology Market for ASD Therapeutics, by Region, Through 2029
Table 21 : Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2029
Table 22 : Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2029
Table 23 : FDA Approved DMTs
Table 24 : Global Neurology Market for Multiple Sclerosis Therapeutics, by Region, Through 2029
Table 25 : Global Neurology Market for Other Disease Therapeutics, by Region, Through 2029
Table 26 : Global Neurology Market, by Region, Through 2029
Table 27 : North American Neurology Market, by Disease Indication, Through 2029
Table 28 : North American Neurology Market, by Country, Through 2029
Table 29 : U.S. Neurology Market, by Disease Indication, Through 2029
Table 30 : Canadian Neurology Market, by Disease Indication, Through 2029
Table 31 : Mexican Neurology Market, by Disease Indication, Through 2029
Table 32 : European Neurology Market, by Disease Indication, Through 2029
Table 33 : European Neurology Market, by Country, Through 2029
Table 34 : German Neurology Market, by Disease Indication, Through 2029
Table 35 : U.K. Neurology Market, by Disease Indication, Through 2029
Table 36 : French Neurology Market, by Disease Indication, Through 2029
Table 37 : Spanish Neurology Market, by Disease Indication, Through 2029
Table 38 : Italian Neurology Market, by Disease Indication, Through 2029
Table 39 : Rest of European Neurology Market, by Disease Indication, Through 2029
Table 40 : Asia-Pacific Neurology Market, by Disease Indication, Through 2029
Table 41 : Asia-Pacific Neurology Market, by Country, Through 2029
Table 42 : Chinese Neurology Market, by Disease Indication, Through 2029
Table 43 : Japanese Neurology Market, by Disease Indication, Through 2029
Table 44 : Indian Neurology Market, by Disease Indication, Through 2029
Table 45 : Rest of Asia-Pacific Neurology Market, by Disease Indication, Through 2029
Table 46 : Rest of the World Neurology Market, by Disease Indication, Through 2029
Table 47 : Key Companies in Alzheimer's Generic Drug Market
Table 48 : Key Companies in Alzheimer's Branded Drug Market
Table 49 : Global Ranking of Leading Manufacturers of ASD Drugs
Table 50 : Information Sources in this Report
Table 51 : Abbreviations Used in the Global Neurology Market Report
Table 52 : AbbVie Inc.: Company Snapshot
Table 53 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 54 : AbbVie Inc.: Product Portfolio
Table 55 : AbbVie Inc: News/Key Developments, 2023 and 2024
Table 56 : Alpha Cognition: Company Snapshot
Table 57 : Alpha Cognition: Financial Performance, FY 2022 and 2023
Table 58 : Alpha Cognition.: Product Portfolio
Table 59 : Alpha Cognition: News/Key Developments, 2024
Table 60 : Biogen.: Company Snapshot
Table 61 : Biogen: Financial Performance, FY 2022 and 2023
Table 62 : Biogen: Product Portfolio
Table 63 : Biogen: News/Key Developments, 2023 and 2024
Table 64 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 65 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
Table 66 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 67 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024
Table 68 : Bristol-Myers Squibb Co.: Company Snapshot
Table 69 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 70 : Bristol-Myers Squibb Co.: Product Portfolio
Table 71 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 72 : Eisai Co. Ltd.: Company Snapshot
Table 73 : Eisai Co. Ltd..: Financial Performance, FY 2022 and 2023
Table 74 : Eisai Co. Ltd.: Product Portfolio
Table 75 : Eisai Co. Ltd.: News/Recent Developments, 2023 and 2024
Table 76 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 77 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 78 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 79 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 80 : H. Lundbeck A/S: Company Snapshot
Table 81 : H. Lundbeck A/S: Financial Performance, FY 2022 and 2023
Table 82 : H. Lundbeck A/S: Product Portfolio
Table 83 : H. Lundbeck A/S: News/Key Developments, 2021 and 2024
Table 84 : Lilly: Company Snapshot
Table 85 : Lilly: Financial Performance, FY 2022 and 2023
Table 86 : Lilly: Product Portfolio
Table 87 : Lilly: News/Key Developments, 2024
Table 88 : Merck & Co. Inc.: Company Snapshot
Table 89 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 90 : Merck & Co. Inc.: Product Portfolio
Table 91 : Merck & Co. Inc.: News/Key Developments, 2023
Table 92 : Novartis AG: Company Snapshot
Table 93 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 94 : Novartis AG: Product Portfolio
Table 95 : Novartis AG: News/Key Developments, 2022 and 2023
Table 96 : Otsuka Holdings Co. Ltd.: Company Snapshot
Table 97 : Otsuka Holdings Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 98 : Otsuka Holdings Co. Ltd.: Product Portfolio
Table 99 : Otsuka Holdings Co. Ltd.: News/Key Developments, 2023 and 2024
Table 100 : Sanofi: Company Snapshot
Table 101 : Sanofi: Financial Performance, FY 2022 and 2023
Table 102 : Sanofi: Product Portfolio
Table 103 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 104 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 105 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 106 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021-2023
Table 107 : UCB S.A.: Company Snapshot
Table 108 : UCB S.A.: Financial Performance, FY 2022 and 2023
Table 109 : UCB S.A.: Product Portfolio
Table 110 : UCB S.A.: News/Key Developments, 2024
List of Figures
Summary Figure : Global Neurology Market Share, by Disease Indication, 2023
Figure 1 : Porter's Five Forces Analysis of the Neurology Market
Figure 2 : Market Dynamics of Neurology Market
Figure 3 : Breakdown of People Aging 65 or Older with Alzheimer's Dementia, 2024
Figure 4 : Global Burden of Conditions Affecting the Nervous System, 2021
Figure 5 : Pipeline Analysis of Some Neurological drugs, by Phases, 2024
Figure 6 : Global Neurology Market Share, by Disease Indication, 2023
Figure 7 : Global Neurology Market Share for Anti-Parkinson's Drugs, by Drug Class, 2023
Figure 8 : Global Neurology Market Share for Anti-Parkinson's Drugs, by Region, 2023
Figure 9 : Global Neurology Market Share for Alzheimer Drugs, by Mechanism of Action, 2023
Figure 10 : Global Neurology Market Share for Alzheimer Drugs, by Region, 2023
Figure 11 : Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2023
Figure 12 : Global Neurology Market Share for Antipsychotic Drugs, by Region, 2023
Figure 13 : Prevalence of Mental Illnesses in U.S. Adult Populations, 2023
Figure 14 : Global Neurology Market Share for Anti-Epileptic Drugs, by Drug Class, 2023
Figure 15 : Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2023
Figure 16 : Global Neurology Market Share for ASD Therapeutics, by Label Information, 2023
Figure 17 : Global Neurology Market Share for ASD Therapeutics, by Region, 2023
Figure 18 : Global Market Share of Brain and Central Nervous System Cases, both Sexes, by WHO Region, 2022
Figure 19 : Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2023
Figure 20 : Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2023
Figure 21 : Prevalence of Multiple Sclerosis Cases in Select Countries, 2019
Figure 22 : Global Neurology Market Share for Multiple Sclerosis Therapeutics, by Region, 2023
Figure 23 : Global Neurology Market Share for Other Disease Therapeutics, by Region, 2023
Figure 24 : Global Neurology Market Share, by Region, 2023
Figure 25 : North American Neurology Market, by Disease Indication, 2021-2029
Figure 26 : North American Neurology Market Share, by Country, 2023
Figure 27 : European Neurology Market, by Disease Indication, 2021-2029
Figure 28 : European Neurology Market Share, by Country, 2023
Figure 29 : Asia-Pacific Neurology Market, by Disease Indication, 2021-2029
Figure 30 : Asia-Pacific Neurology Market Share, by Country, 2023
Figure 31 : Rest of the World Neurology Market, by Disease Indication, 2021-2029
Figure 32 : Share of Major Players in Anti-Parkinson's Drugs Market, 2023
Figure 33 : Share of Major Players in Antipsychotic Drugs Market, 2023
Figure 34 : Share of Major Players in Anti-Epileptic Drugs Market, 2023
Figure 35 : Share of Major Players in Brain Tumor Therapeutics Market, 2023
Figure 36 : Share of Major Players in Multiple Sclerosis Therapeutics Market, 2023
Figure 37 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 38 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 39 : Biogen: Revenue Share, by Business Unit, FY 2023
Figure 40 : Biogen: Revenue Share, by Country/Region, FY 2023
Figure 41 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
Figure 42 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
Figure 43 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 44 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 45 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 46 : Eisai Co. Ltd.: Revenue Share, by Region/Country, FY 2023
Figure 47 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 48 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 49 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2023
Figure 50 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2023
Figure 51 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 52 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 53 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 54 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 55 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 56 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 57 : Otsuka Holdings Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 58 : Otsuka Holdings Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 59 : Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 60 : Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 61 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 62 : UCB S.A.: Revenue Share, by Business Unit, FY 2023
Figure 63 : UCB S.A.: Revenue Share, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security